Joachim G.
- Country
- Germany
- Department
- #2506: Klinik für Haematologie und Stammzelltransplantation
Research Overview
- Phase 1 Evaluation of JNJ-88549968, a T-cell Redirecting Antibody, in Patients with CALR-mutated Myeloproliferative Neoplasms
- A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
- Evaluation of Tolerability and Efficacy of Asciminib Hydrochloride Versus Nilotinib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Data & Insights
Has run more than one trial at 24 of 95 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating chronic myeloid leukemia (CML), with particular focus on developing innovative therapeutic approaches for newly diagnosed patients.
- Philadelphia chromosome positive CML
- BCR-ABL1 targeted therapies
- Frontline treatment strategies
The investigator evaluates novel therapeutic combinations and treatment tolerability in CML patients.
Myeloproliferative Disorders
Research interests extend to myeloproliferative neoplasms, particularly focusing on high-risk conditions affecting blood cell production.
- Polycythemia vera
- Essential thrombocythemia
- JAK inhibitor therapies
The investigator explores comparative treatment approaches for patients with advanced myeloproliferative conditions.
Therapeutic Development
Expertise in evaluating targeted molecular therapies for hematologic disorders, with emphasis on treatment optimization.
- Novel therapeutic agents
- Treatment tolerability assessment
- Molecular response monitoring
The investigator focuses on developing effective treatment strategies for blood disorders through innovative therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.